On Sunday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced multiple program updates, including: In December, the FDA approved Vertex's Alyftrek (vanzacaftor / tezacaftor ...

Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the published ...

Jefferies analyst Michael Yee has maintained their bullish stance on VRTX stock, giving a Buy rating today. Discover outperforming stocks and invest smarter with Top Smart Score Stocks Filter ...

Citi analyst Geoff Meacham maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price target of $575.00. The company’s shares closed last Friday at ...

View Vertex Pharmaceuticals Incorporated (VRTX) current and estimated P/E ratio data provided by Seeking Alpha.